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The process of angiogenesis is under complex regulation
in adult organisms, particularly as it often occurs in an
inflammatory post-wound environment. As such, there
are many impacting factors that will regulate the genera-
tion of new blood vessels which include not only pro-
angiogenic growth factors such as vascular endothelial
growth factor, but also angiostatic factors. During initial
postwound hemostasis, a large initial bolus of platelet
factor 4 is released into localized areas of damage before
progression of wound healing toward tissue homeostasis.
Because of its early presence and high concentration, the
angiostatic chemokine platelet factor 4, which can induce
endothelial anoikis, can strongly affect angiogenesis. In
our work, we explored signaling crosstalk interactions
between vascular endothelial growth factor and platelet
factor 4 using phosphotyrosine-enriched mass spectrom-
etry methods on human dermal microvascular endothelial
cells cultured under conditions facilitating migratory
sprouting into collagen gel matrices. We developed new
methods to enable mass spectrometry-based phos-
phorylation analysis of primary cells cultured on collagen
gels, and quantified signaling pathways over the first 48 h
of treatment with vascular endothelial growth factor in the
presence or absence of platelet factor 4. By observing
early and late signaling dynamics in tandem with correla-
tion network modeling, we found that platelet factor 4 has
significant crosstalk with vascular endothelial growth fac-
tor by modulating cell migration and polarization path-
ways, centered around P38 MAPK, Src family kinases
Fyn and Lyn, along with FAK. Interestingly, we found
EphA2 correlational topology to strongly involve key
migration-related signaling nodes after introduction of
platelet factor 4, indicating an influence of the angiostatic
factor on this ambiguous but generally angiogenic signal
in this complex environment. Molecular & Cellular Pro-
teomics 12: 10.1074/mcp.M113.030528, 3704–3718, 2013.
Angiogenesis, the formation of blood vessels from pre-
existing blood vessels, is a complex process essential for
repairing injured tissue or supporting tissue growth. A great
deal of work has been done to focus on understanding this
phenomenon as it occurs in vivo, in particular with regard to
its roles in embryonic development (1–5). In contrast to em-
bryonic development, adult angiogenesis and inflammation
are closely related phenomena that occur in vivo in a number
of physiologically relevant processes. Inflammation lies at the
crux of multiple physiological events in biological systems
that precede the induction of angiogenesis: wound healing
(6–8), chronic wounds (8), inflammatory disorders (9, 10), and
cancer (9, 11, 12).
Inflammatory reactions also confound tissue engineered
implantable three-dimensional constructs that provide inno-
vative clinical treatments of various diseases and injuries (13–
17). As complex tissues become developed for applications in
clinical trials, tissue vascularization for constructs of consid-
erable size and volume is required for their survival (18, 19).
Once implanted, these constructs will also experience signif-
icant inflammatory responses within their host’s local milieu
(20, 21). These circumstances demonstrate the necessity for
understanding the interactions between inflammation and an-
giogenesis, such as the development of predictive models
(22). Elucidating specific intracellular mechanisms can pro-
vide insight for novel approaches in treatment of diseases as
well as predicting responses to artificially engineered tissues.
Recently, studies have shown that chemokines, which play
a central role in inflammation, can influence the outcomes of
angiogenesis (23–26) by promoting new blood vessel growth
(e.g. CXCL1–3, CXCL5–8, CXCL12) or inhibiting its formation
altogether (e.g. CXCL4, CXCL9–11, CXCL13) (26). In particu-
lar, a large body of information is available on platelet factor 4
(PF-4/CXCL4) and its ability to inhibit and even induce regres-
sion of angiogenesis. PF-4 is found throughout the adult
body, at roughly 0.25–1.25 nM (2–10 ng/ml) in blood plasma,
From the ‡Department of Biological Engineering, Massachusetts
Institute of Technology, Cambridge, Massachusetts 02139; §Depart-
ment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania
15213
Author’s Choice—Final version full access.
Received April 30, 2013, and in revised form, September 2, 2013
Published, MCP Papers in Press, September 9, 2013, DOI 10.1074/
mcp.M113.030528
Research
Author’s Choice © 2013 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at http://www.mcponline.org
3704 Molecular & Cellular Proteomics 12.12
but as high as 25 M in localized areas during wound healing
(27, 28). Its ubiquitous presence, implication in cancer and
vascular diseases, and use as a potential drug therapy have
made PF-4 a key point of interest in influencing angiogenesis
in vivo (27–30). In addition to inducing angiostasis, PF-4 can
inhibit cell proliferation by halting S phase progression and
reducing endothelial cell migration (25, 28, 30–32). Despite
the wealth of information on PF-4 and its mechanistic effects
on immune cells, scarce literature exists on the nature of the
molecular signaling with endothelial cells to inhibit angiogen-
esis. Furthermore, the complexity of PF-4 mediated signaling
and its potential to interact through multiple binding mecha-
nisms makes it difficult to determine how PF-4 can interfere
with angiogenesis (28, 29, 33, 34). Possible angiogenic
signaling network interference mechanisms for PF-4 include
the sequestration of growth factors and proteoglycans, an-
tagonism of integrin-mediated signaling, or direct signaling
through its chemokine receptor CXCR3, all of which have
supporting evidence in previous literature (28). Along with the
multiple mechanisms PF-4 may utilize for signaling, only lim-
ited studies on direct signaling elicited by PF-4 on endothelial
cells have been reported; one of interest found that P38
MAPK can be activated via CXCR3 on endothelial cells cul-
tured on plastic (35), whereas another, more definitive study
showed PF-4 acting similarly to other CXCR3 ligands in acti-
vating PKA to prevent m-calpain-mediated rear de-adhesion
of moving cells (36, 37). Furthermore, PF-4 could have vari-
able sensitivities in different endothelial cell types because of
heterogeneous expression of CXCR3 (38).
In our study, we sought to develop an approach to assess
network-level signaling interactions between PF-4 and the
major angiogenic inducer vascular endothelial growth factor
(VEGF)1 within a contextually relevant 3-D angiogenesis plat-
form, in a controlled environment to understand what role
these two factors may play. We developed methods to reduce
extracellular matrix contamination in our samples and were
able to successfully use a two-step lysis method with a MS
compatible detergent-based lysis buffer. By taking advantage
of iTRAQ-based multiplexed quantitation, we were able to
collect quantitative phosphoprotein signaling data from our
system with early and late temporal resolution. Using corre-
lation network methods to observe differences in our system,
we found that simultaneous treatment with PF-4 and VEGF
induced changes in migrational pathway topology when com-
pared with VEGF treatment alone. Most often, these changes
appeared as losses in correlations between different migra-
tional signaling proteins. We found that several different sig-
naling pathways involved with migration were affected, in-
cluding central proteins P38 MAPK, focal adhesion kinase
(FAK), and Src family kinases. Furthermore, we found statis-
tically significant differences in tyrosine phosphorylation when
HDMVECs were stimulated with VEGF and PF-4, as opposed
to only VEGF. In addition, we were able to recapitulate previ-
ously reported findings on how PF-4 infers its angiostatic
effects on endothelial cells. Surprisingly, our data set revealed
EphA2 receptor as a central node for PF-4 signaling, indicat-
ing that it may possess a complementary role in the balance
of angiogenic and angiostatic effects.
To our knowledge, this is the first attempt at performing
MS-based analysis of phosphotyrosine signaling networks
within the context of an environment that is amenable to
angiogenesis. Our work provides a step forward in applying
high throughput and systems-level phosphoproteomics
data collection to more physiologically relevant experimen-
tal conditions.
EXPERIMENTAL PROCEDURES
Cell Culture—Adult HDMVECs were purchased at passage five
(Lonza, Walkersville, MD). Cells were cultured in EGM-2MV (Lonza)
medium until near confluency. Once near confluency, cells were
rinsed with 1 PBS (Invitrogen, Grand Island, NY) and detached by
incubating with 0.05% Trypsin-EDTA (Invitrogen) for 3–5 min at 37 °C
and 5% CO2. Trypsin was neutralized by the addition of EBM-2
(Lonza) with 5% FBS (Thermo Fisher Scientific/Hyclone, Logan, UT)
and 50 g/ml gentamicin (Sigma-Aldrich, St. Louis, MO). Cells were
pelleted at 450  g for 5 min and resuspended in EGM-2MV before
being seeded onto 50 g/ml rat tail collagen I (BD Biosciences,
Bedford, MA) coated tissue culture flasks at 5000 cells/cm2. Medium
was changed 24 h following seeding and replaced once every 48 h
until nearing confluency. HDMVEC were grown up to passage 9 for
use.
Collagen Gel Cultures—Collagen gels cultures were used to study
capillary sprouting, as performed in a parallel study on HDMVEC
migrational phenotype (22). Collagen gel solutions were made using
10 PBS (10%), collagen solution stock, and 1N NaOH (Sigma-
Aldrich) added at 2.3% of the collagen stock solution volume used.
Sterile MilliQ purified water was added to reach the desired total
volume and kept on ice until use. One milliliter of collagen gel solution
was added to each well in six-well plates (9.6 cm2 per well). Gels were
formed at a density of 2.0 mg/ml at approximately a pH of 7.2, and
allowed to set at 37 °C for 2 h before being rinsed with 1 PBS. Gels
were then preconditioned with EBM-2 with 5% FBS and 50 g/ml
1 The abbreviations used are: ANXNA1, Annexin A1; BCAR-1,
Breast Cancer Anti-Estrogen Resistance 1; Cas1, CDK1, Cyclin De-
pendent Kinase 1; CTNND1, Catenin Delta 1 Isoform 1A (p120CAS);
DYRK1B, Dual-Specificity Tyrosine-Phosphorylation Regulated Ki-
nase 1B; DTT, Dithiothreitol; EBM, Endothelial Basal Media; EGM,
Endothelial Growth Media; EphA2, Ephrin receptor EphA2; ephA1,
Ephrin ligand A1; FAK, Focal Adhesion Kinase/Protein Tyrosine Ki-
nase 2 (PTK2); FBS, Fetal Bovine Serum; HDMVEC, Human Dermal
Microvascular Endothelial Cell; LC/MS/MS, Liquid chromatography
tandem mass spectrometry; MAPK - Mitogen Activating Protein Ki-
nase; Akt/PKB, Protein Kinase B; P38, P38 MAPK/Mitogen-Acti-
vated Protein Kinase 14 ; PI3K, Phosphatidylinositide-3-kinase;
PRP4K, Serine/Threonine Protein Kinase PRP4K; ErbB2IP, ErbB2
Interacting Protein; MPZL1, Myelin Protein Zero-Like 1; CD31, Plate-
let/Endothelial Cell Adhesion Molecule 1 (PECAM-1); IP, Immunopre-
cipitation; PBS-T, 0.1% Tween in 1X PBS; PF-4 - Platelet Factor 4;
PKA, Protein Kinase A; PTPR, Protein Tyrosine Phosphatase; Re-
ceptor Type Alpha; PTPR, Protein Tyrosine Phosphatase; Receptor
Type Epsilon; PXN, Paxillin; RTK, Receptor Tyrosine Kinase; SHC1,
SHC transforming protein 1; SHP2, Protein Tyrosine Phosphatase;
Non-receptor Type 11 (PTPN11); VEGF, Vascular Endothelial Growth
Factor.
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gentamicin for 2 days to minimize background changes and nonspe-
cific ligand binding when dosing conditions were introduced to cells
seeded on the gels.
HDMVEC were thawed and grown on 50 g/ml collagen I coated
tissue culture flasks up to passage 9, collected as above and counted
using Neubauer-improved disposable C-Chip hemocytometers
(INCYTO, Seoul, Korea) and seeded onto collagen gels at 50,000
cells/cm2. Cells were allowed to adhere for 4–6 h at 37 °C in 5% CO2
before rinsing with PBS and replacing the media with EBM-2  5%
FBS and gentamicin. HDMVEC were allowed to incubate overnight.
24 h after seeding, plates of HDMVEC were dosed with 20 ng/ml
VEGF-165 (Peprotech, Rocky Hill, NJ) and with or without 500 ng/ml
PF-4 (Peprotech) across designated time intervals (0 min, 15 min, 30
min, 60 min, 6 h, 24 h, and 48 h). The concentration of PF-4 was
selected based on results from previous work on HDMVEC (36, 37). In
addition to significant dilution of precursor strength (see phosphoty-
rosine mass spectrometry and manual validation of mass spectral
fragments in Supplemental Data), high error amplification, and previ-
ously reported dependence of the angiostatic behavior of PF-4 on the
presence of angiogenic growth factors (28), the inclusion of a no
VEGF (0 ng/ml) condition was omitted following initial testing.
Confocal Microscopy—Collagen gels were formed on 24 well glass
bottom MatTek plates (MatTek Corporation, Ashland, MA) and
HDMVEC were seeded following the protocol described above. Four
hours after seeding, media were replaced with EGM-2MV  20 ng/ml
VEGF (40 ng/ml total). After 72 h, samples were fixed with 4% para-
formaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 30 min
and rinsed gently with PBS before being permeabilized with 0.1%
Triton-X (Sigma-Aldrich) in PBS. The fixed samples were incubated
with 1:100 Alexa 568-conjugated phalloidin (Invitrogen) for actin fila-
ments and 1:200 rabbit polyclonal anti-vascular endothelial cadherin
(VE-cadherin) antibody (Enzo Life Sciences, Farmingdale, NY) in 1
PBS with 0.5% BSA for 1 h before being rinsed with PBS. Samples
were then stained with 1:1000 DAPI (Invitrogen) and imaged on an
Olympus FV1000 Multiphoton Laser Scanning Confocal Microscope
using Imaris 7.0.0 (Bitplane, South Windsor, CT).
Microfluidic Migration Assay Platform—These follow protocols as
described previously (22, 39). For more information, please refer to
Supplemental Data and Methods.
Detergent Surface Lysis With Subsequent Urea Lysis—Detergent-
based lysis buffer was made following previously established proto-
cols (40). Slight modifications were made to the base protocol to
maintain compatibility with MS lysate preparation protocols. Cell lysis
buffer consisted of 1% Triton X-100, 50 mM -glycerophosphate, 10
mM sodium pyrophosphate, 30 mM sodium fluoride (Sigma-Aldrich),
50 mM Tris (Roche Applied Science, Indianapolis, IN), 150 mM sodium
chloride, 2 mM EGTA, 1% Protease Inhibitor Mixture (Sigma-Aldrich)
and 1% Phosphatase Inhibitor Mixture Sets I and II (EMD Calbi-
ochem, Gibbstown, NJ). Following a rinse with cold PBS with the
plates on ice, 200 l of cold lysis buffer were gently added to the top
of each gel. Plates were then quickly transferred to a Model 1000
standard orbital shaker (VWR International, Radnor, PA) set at 185
rpm for 15 min at 4 °C. Following lysis, lysate from each well of a
six-well plate was consolidated into one sample, defined as a biolog-
ical replicate in our analysis at 1.2 ml volume and mixed with 3.6 ml
of 8 M urea with 1 mM activated sodium orthovanadate (Sigma-
Aldrich) to a final urea concentration of 6 M. Samples were then
immediately snap frozen in liquid nitrogen before placing into storage
at 80 °C.
Western Blotting—Signaling in HDMVEC seeded on collagen gels
was assessed under the dosing conditions indicated above. Samples
were then lysed using the detergent-based lysis buffer described
above for MS sample preparation. In addition to the components
listed above, 1 mM DTT and 1 mM PMSF were included to prevent
phosphatase activity and protein degradation (40). Six-well plates
were placed on ice and rinsed with cold PBS before the addition of
200 l of lysis buffer to each well. Cell scrapers were used to break up
the collagen gel and facilitate lysis of cells. Samples were collected
and spun down in an ultracentrifuge at 14,000 rpm (16,000 g) for
12–15 min until debris was pelleted from the supernatant. The Nu-
Page Novex System (Invitrogen) was used to run gel electrophoresis,
where lysates were loaded with 6 reducing buffer (Boston BioProducts,
Worcester, MA) in 4–12% Bis-Tris gels (Invitrogen) and transferred
to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA). Mem-
branes were blocked with 5% BSA in 0.1% Tween in PBS (PBS-T)
and incubated with antibodies for -actin (1:5000), / tubulin (1:
5000), phospho-ERK1/2 (1:5000), phosphoY772-EphA2 (Tyr772) (1:
1000) (Cell Signaling Technology, Beverly, MA), and EphA2 (1:1000)
(Cell Applications, San Diego, CA) overnight at 4 °C. Membranes were
washed and then incubated for 1 h with horseradish peroxidase-
conjugated antimouse and/or antirabbit antibodies (Amersham Bio-
sciences/GE Healthcare Biosciences, Pittsburgh, PA) at 1:10,000 di-
lution in PBS-T with 5% blotting grade nonfat dry milk (Bio-Rad).
Membranes were subsequently visualized using chemiluminescent
ECL kits (Amersham Biosciences/GE Healthcare Biosciences) on a
Kodak Image Station (Perkin Elmer, Waltham, MA).
Phosphotyrosine Mass Spectrometry—Sample processing fol-
lowed protocols for chemical reduction, alkylation, trypsin digestion,
and fractionation as previously described (41, 42). Briefly, groups of
eight samples were labeled with eight unique isobaric iTRAQ reagents
(AB SCIEX, Framingham, MA) for 2 h at room temperature. Following
labeling, samples were combined and concentrated before immuno-
precipitation (IP) with a mixture of antiphosphotyrosine antibodies
(4G10 (Millipore, Billerica, MA), pTyr100 (Cell Signaling), and PT-66
(Sigma), 12 g of each) immobilized onto protein G agarose beads
(Calbiochem) in iTRAQ IP buffer (100 mM Tris, 100 mM NaCl, 0.3%
Nonidet P-40, ph 7.4) (Sigma-Aldrich) overnight at 4 °C. Beads were
washed four times in rinse buffer (IP buffer without Nonidet P-40) and
phosphotyrosine-containing peptides were eluted with glycine buffer
(100 mM, pH  2) at room temperature for 30 min on a rotator.
Phosphopeptides were further enriched by immobilized metal affinity
chromatography (IMAC) on a custom-packed 200 m  10 cm col-
umn with Poros MC 20 m beads (Invitrogen). Phosphopeptides were
eluted with phosphate buffer (250 mM, pH 8.0) directly onto a custom
100 m x 10 cm precolumn packed with 10 m YMC-Gel ODS-A
beads (Waters Corporation, Milford, MA). The precolumn was imme-
diately washed and brought in line with a custom 50 m  10 cm
analytical column packed with 5 m YMC-Gel ODS-AQ beads with
120 angstrom pores (Waters Corporation), and with an integrated
sub-m nanospray tip pulled with a laser puller (Sutter, Novato, CA).
Each tip was examined by microscopy with a calibrated objective and
tested extensively with single femtomolar quantities of peptide stand-
ards before use. Analysis and quantification of eluted peptides were
conducted on an Orbitrap Elite mass spectrometer via nano-ESI
LC/MS/MS (Thermo Fisher Scientific) with a tandem MS top ten
data-dependent acquisition method. Peptides were eluted with a
binary gradient with an aqueous solvent of 0.2 M acetic acid in
ultrapure water and an organic solvent of 0.2 M acetic acid in 90%
acetonitrile and 10% ultrapure water. The gradient was 0–13% or-
ganic from 0 to 10 min, 13% to 42% from 10 to 105 min, 42% to 60%
from 105 to 115 min, 60% to 100% from 115 to 120 min, held at
100% organic from 120 to 128 min, and washed indefinitely with
aqueous solvent until peptides stopped eluting. The flow rate was
initially set at 20 nL/min and then dropped to 5–10 nL/min once
peptides began eluting.
Raw files were processed with MSQuant v2.0b7 software and
DTASupercharge (43), followed by peptide sequence and protein
identification with Mascot v2.1.03 (Matrix Science, Boston, MA) (44).
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Mascot searches were run in MS/MS ion search mode with the
following parameters. Fixed modifications included iTRAQ8plex (K,
N-term), and Carbamidomethyl (C), whereas variable modifications
were Oxidation (M), Phospho Serine/Threonine (ST), and Phospho
Tyrosine (Y). Monoisotopic mass values were selected with no restric-
tions on protein mass. A tolerance of 10 ppm was selected for peptide
mass and 0.8 Da for fragment mass tolerance, with a maximum of two
missed trypsin cleavages permitted. The instrument type was spec-
ified as an LTQ-Oribitrap. Because the culture system of HDMVECs
was human in origin, the database was limited to the 2009 NCBI
human proteome database in all searches (H. sapiens), with 37,743
total entries. The top 1000 peptide hits were reported, neglecting
protein significance score cutoffs, because of the extensive phos-
photyrosine enrichment performed. Because of the challenges
associated with using a collagen gel culture system, an initial MASCOT
peptide score threshold of 20 was implemented before initial data
processing and normalization to protein supernatant values. In the
cases of multiple matches, the query with the highest score and
smallest expect value from Mascot was selected. For search results
file outputs (both phosphotyrosine enriched immunoprecipitates
and IP supernatants), please see Supplemental Data. All mass
spectrometry proteomics data were deposited to the Proteom-
Xchange Consortium (http://proteomecentral.proteomexchange.org)
via the PRIDE partner repository with dataset identifier PXD000462
(114).
Manual Validation of Mass Spectra Fragments—Because our work
involved specific phosphorylation of amino acid residues, each tyro-
sine phosphorylation site was subjected to manual validation. Phos-
phopeptide scores and signals were thresholded for significant hits
(score 20) and values were normalized to a master lysate (50 ng/ml
VEGF treatment for 15 min) and normalized to total protein values
obtained from an LC/MS/MS analysis of iTRAQ channel intensities of
the IP supernatant. Initial methods to normalize to a master control
condition with no stimulation (no VEGF) yielded a response with high
noise to signal amplification because of the absence or minimal signal
present in this condition. Each nonzero normalized mass spectra
output (where iTRAQ for at least 5 of 8 tags were nonzero) was
manually validated by hand following previously described guidelines
to ensure correct sequence identification and phosphosite assign-
ment (45). Peaks were compared with theoretical values for each of
the peptides assigned by Mascot using the MS-Product component
of Protein Prospector v5.10.9 (Baker, P.R. and Clauser, K.R. http://
prospector.ucsf.edu). The processed, validated mass spectra data
are also included in the Supplemental Data, as well as scans that were
rejected because of precursor contamination, as indicated in the
added header on each scan plot. Amino acid residue locations of
phosphorylations on peptides were verified using PTMScout (46) in
addition to the aforementioned manual validation.
Data Processing and Statistical Analysis—Data from three biolog-
ical replicates (with two technical replicates per biological sample)
were consolidated into one data set for assessing phosphoprotein
levels. To quantify across the six mass spectrometry analyses, a
master lysate sample included in each batch of samples processed
for mass spectrometry was used as a normalization factor to compare
across several runs. Statistical analysis of time course data was
performed using Student’s t test (Microsoft Excel). Methods to quan-
tify signaling node relatedness using correlation network modeling
follow those previously described (47). At every time point, geometric
means of the phosphorylation fold change relative to a master lysate
were calculated for each protein that had at least two nonzero mea-
surements across two biological replicates (two technical replicates
each). For time points and proteins where only one measurable MS
value was collected and identified from the total pool of replicates
performed, the single replicate value was used as a measure of best
estimate of phosphorylation.
Of the resulting MS data, 37 phosphosites fulfilled the full time
course criterion for initial modeling setup. Pearson correlation coef-
ficients were calculated between each pair of phosphosites using the
37  6 data matrix. Statistical significance of pairwise correlation
coefficients was assessed using the permutation test by shuffling
time course data (n  100,000). The overall data set provided 37 
36/2  666 unique pairwise correlation coefficients and p values
(self-correlations ignored).
RESULTS
Optimization of Collagen Gel Culture System for Collection
of Phosphoprotein Signaling Data—HDMVEC seeded on col-
lagen gels had the capability to undergo sprouting (Fig. 1,
Video S1). Although the occurrence of sprouting events are
generally uncommon in vivo (as only a few cells eventually
break away from the bulk), the collagen gel culture system
provided us with both a system that could provide quantita-
tive intracellular signaling analysis and the future potential to
capture extracellular endothelial response behaviors associ-
ated with angiogenesis. However, conventional methods of
harvesting cell lysates provided either insufficient total pro-
tein, large volumes of diluted samples, or excess collagen.
Multiple alternative methods were evaluated for maximizing
cell lysate retention for efficacious processing. These includ-
ed: (1) centrifugation of urea-lysed samples with collagen
gels; (2) urea-lysis, freezing, thawing, and centrifugation of
samples; (3) urea-lysis and syringe filtration of lysate using
0.22 m filter; (4) initial cell detachment using collagenase
cocktails followed by urea lysis; (5) urea lysis followed by IP
incubation with collagen antibodies; (6) centrifugation of de-
tergent-lysed cells followed by acetone precipitation and re-
suspension in urea lysis buffer; and (7) surface lysis of HDM-
VECs followed by suspension in urea buffer. Lysis procedures
of samples grown on collagen gels were assessed by visual-
izing phospho- and total ERK1 and 2 levels, and surface lysis
protocols were found to provide the best results. The assess-
ment validated our ability to detect phosphoproteins using
surface lysing protocols, thereby indicating that we could
potentially detect phosphorylation sites with the use of the
collagen gel system with mass spectrometry methods (see Sup-
plemental Data, Fig. S1). In addition, other phospho-peptides
(P38, Akt, PKA) were also evaluated during the validation pro-
cess (data not shown).
Time-resolved Tyrosine Phosphorylation Measures by Quan-
titative Mass Spectrometry Indicate Statistically Significant Dif-
ferences over the Course of Stimulation—Following manual
validation of spectra outputs, 133 phosphorylation sites
across 92 proteins were observed in our data set. Out of the
92 unique proteins identified, 33 proteins identified had at
least one measurable scan for more than one condition (37
phosphosites overall). Of these 33 proteins, we observed 22
proteins that had statistical data available at all time points
tested for both treatment conditions (26 total phosphosites
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with statistical data), where 17 of the proteins had statistically
significant differences following the addition of PF-4. The
temporal signaling dynamics for these proteins are shown in
Fig. 2, with the statistical significance marked by their respec-
tive levels. These data were interpreted as a comparison
between VEGF only and VEGF cotreatment with PF-4 as
crosstalk pathway activation because of the presence of
PF-4. A third treatment condition with PF-4 by itself in ab-
sence of VEGF did not exhibit any large, statistically signifi-
cant effects on phosphorylation compared with the control
condition (data not shown), and hence comparisons were
made with VEGF present in both conditions. The condition of
no stimuli (no VEGF, no PF-4) was not included because
of initial analysis yielding little or no signal present. The lack of
significant differences for PF-4 only treatments does not nec-
essarily rule out the importance of independent signaling by
PF-4. Most likely, the preponderance of PF-4’s impact on
signaling occurs in conjunction with angiogenic signaling pro-
cesses as a potential modulatory influence.
There was a persistently higher level of Annexin A2 phos-
phorylation for the majority of the time course when PF-4 was
present, which became lower at later time points. On the other
hand, Annexin A1 experienced an early attenuation of signal
intensity at 15 min when PF-4 was present, although signaling
became indistinct from conditions where PF-4 was absent.
Cell cycle regulating protein cyclin dependent kinase 1 (Cdk1)
appeared to have an initial decrease in signal followed by a
delayed response in activation when PF-4 was present. For
Ephrin A2 receptor (EphA2), whereas a stark drop in signal
occurred at 30 min when HDMVEC were dosed with VEGF,
PF-4 treatments experienced an increase in signaling. Simi-
larly, Src family kinases Fyn and Lyn experienced an increase
of phosphorylation in early time points when both PF-4 and
VEGF were present. Interestingly, both experienced a sharp
decline during signaling around 60 min compared with VEGF
treatment only. On the other hand, FAK appeared to have an
attenuated phosphorylation signal at 60 min before being
much more actively phosphorylated at later time points. Dual
phosphorylation of P38 at T180 and Y182 decreased at 15
min in the presence of PF-4, although relative phosphorylation
levels of Y182 increased at 30 min. Paxillin and CD31 both
had higher phosphorylation expression levels when PF-4 was
present relative to VEGF treatment by itself, indicating that
they may be positive signaling mechanisms employed by
PF-4, although there was no statistical significance observed
between the two conditions (p  0.05).
Many of the other proteins shown in Fig. 2 had complex
signaling which were difficult to interpret because of lack of
FIG. 1. Collagen gel culture enables signaling analysis of endothelial sprout initiation. Sprouting events could be observed within 24 h
after HDMVEC seeding on collagen gels. Actin filaments were stained with phalloidin (red) and cell nuclei were stained with DAPI (blue) and
VE-Cadherin (green). A general schematic of the collagen gel set-up is shown with multiple sprouts observed in the yellow circles 18 h after
seeding (A). A higher magnification and its respective Z projection of an initiated sprout into the collagen are shown for a selected sprout.
Orthogonal Z projections of an HDMVEC culture into a collagen gel are shown after 72 h (B), with significant invasion into the collagen gel. The
gel cultures are more physiologically representative of the environment that endothelial cells observe in vivo, as opposed to strictly culturing
on tissue culture plastic which do not allow angiogenic behavior to be simulated or observed. Using this culture system, we were able to
observe angiogenic sprouting as well as signal transduction pathways relevant to the process. Scale bars  100 m.
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statistical significance (p  0.05) and/or very minor difference
in phosphorylation between the two treatment conditions.
Although statistical significance was found to occur at various
points in time for the different signaling proteins in the data
set, the majority of these significant differences occurred at
early time points within the first hour of dosing, indicating that
most of the phenotypic responses mediated by these two
signaling molecules were dictated by early exposure to these
cytokines rather than later signaling. These complex signaling
dynamics include receptor protein tyrosine phosphatases
PTPR and PTPR, CD31, pragmin, and cdk1. In fact, ob-
serving the behavior of cdk1 across time appears counterin-
tuitive as well; rather than expecting PF-4 to inhibit mitosis as
observed in previous findings (32), the presence of PF-4 ac-
tually reduces the phosphorylation levels at 30 min relative to
the sole treatment with VEGF. However, a caveat of the pre-
vious findings were from cells cultured on coated plastic,
which may have inherent differences from the environmental
FIG. 2. Signaling dynamics from time resolved tyrosine phosphorylation measurements by quantitative mass spectrometry. Of the
133 manually curated phosphorylation sites, only 37 had a full time course data set, with 22 phosphosites having at least two readings per time
point in both treatment conditions. The phosphorylation level of these sites is provided for two different treatment conditions: 20 ng/ml VEGF
(VEGF), and 20 ng/ml VEGF  500 ng/ml PF-4 (VEGF  PF-4). Raw signal measurements were normalized to total protein values and reported
as relative proportions to a master lysate stimulated with saturating 50 ng/ml VEGF. Notable temporal increases in signaling dynamics following
PF-4 cotreatment were observed for Annexin A2(Y24), EphA2(Y772), Fyn(Y420), GSK3 (Y216), Lyn(Y397), P38(Y182), Paxillin(Y118), and
SHC1(Y318). Attenuations in signaling were noticed for Annexin I(Y21), DYRK1B(Y273), and focal adhesion kinase FAKY576) with PF-4 present.
Changes were not mutually exclusive in the same time course data as both increases and decreases in phosphoprotein levels were observed
at different time points for many of these proteins as well as Cdk1(T14/Y15) and MPZL1(Y263). Treatment with PF-4 alone yielded
noninformative results. Statistical analyses performed using Student’s t test found a majority of statistically significant differences to occur in
early time points (first 60 min), indicating that early signaling most likely informs endothelial response. Errors bars represent standard error.
Statistical significance indicated by asterisks: * for p  0.05, ** p  0.01, and *** p  0.001.
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context applied here. Although there is a delayed increase in
Thr14/Tyr15 phosphorylation at 60 min, simultaneous treat-
ment with PF-4 maintain a slightly lower level of this inhibitory
phosphorylation.
Significant Phosphoprotein Sites That are Detected Are
Strongly Associated With Influencing Cell Migration Pathways—
Following manual validation of the tandem mass spectra,
the remaining phosphosites in the curated data were evalu-
ated using reports in previous literature to determine their
potential roles here in inflammatory angiogenesis pathways.
These functions are reported in the table, along with their
sources and alternative names (Table I). Most of the phos-
phosites are known to be involved in cell polarization and
migration activity, including phosphosites on FAK, Src family
kinases, Cas1, and Paxillin. Although the functional associa-
tion of these sites were determined in cell lines, they are
known to perform similar or identical functions across many
different cell types as well as across species that have ho-
mologous proteins; it is therefore likely that these functions
are recapitulated in this context.
Correlation Network Modeling Reveals Significant Changes
in Protein Interactions Involved in Inhibiting Cell Migration
Mechanisms—With a relatively large data set, it is difficult to
infer the exact mechanisms by which the introduction of PF-4
changes the overall signaling landscape in HDMVEC angio-
genesis. To make sense of the time course data, a network
correlation model was employed to evaluate the topology
changes in signaling pathways between the two treatment
conditions. Pearson’s pairwise linear correlation coefficients
were evaluated and compared for differences between the
two conditions, with the strength of the correlations shown as
a heatmap (Fig. 3). A considerable number of proteins in the
data set did not possess more than one replicate at each time
point for the two conditions tested. To expand our analysis
beyond the 22 phosphosites and provide a wider breadth of
coverage, we used the single replicate as a representation of
the signaling intensities to increase our analysis to include 37
phosphosites. Overall, there appeared to be many negative,
or low correlations present in the data set, particularly with
proteins associated with BCAR-1 (Cas1) such as FAK,
P38alpha, Fyn, and protein tyrosine phosphatases (Fig. 3A).
On the introduction of PF-4, many of these correlations are
reversed; in fact, there are a greater number of strong, positive
correlations when VEGF and PF-4 are co-treated (Fig. 3B).
For example, although ErbB2IP/Erbin was positively corre-
lated with almost all proteins except BCAR-1/Cas1, GSK3,
Paxillin, Pragmin, TIE1, Tyk2, and SHB in VEGF treatments,
these positive correlations all became inversely correlated or
reduced in strength following co-treatment with PF-4. In ad-
dition, Shp2, PLC, MPZL1, and P38 are new, strongly
negative correlations with Erbin following PF-4 treatment.
These inversions in correlation trends were similarly observed
for most of phospho-Y575 EphA2 and FAK interactions (Fig.
3B). Likewise, many other proteins had the opposite trends in
correlations occur, including many of the associations with
phospho-Y257 Catenin 1 and Src family kinase Fyn (Fig. 3).
To reduce the number of observations made, as well as to
extract the most accurate and significant data from signaling
TABLE I
Important phosphorylation sites involved with PF-4 and VEGF crosstalk and their previously reported functions. A subset of the phosphorylation
sites found to be involved with PF-4 and VEGF signaling in the sprouting angiogenesis data set is highlighted in this table, including 22 of the
37 phosphoproteins that were found to have complete coverage across all time points in the data set. Previously reported functions for these
proteins and phosphorylations are shown from different cell systems, as well as some that have been reported to play roles in angiogenesis.
Although they may have been reported to have roles in other cell phenotypes, there may be overlap with the PF-4 and VEGF signaling system,
such as the potential importance of cell migration and polarization in orchestrating blood vessel formation
Protein name (and Aliases) Phosphorylation(s) Reported functions References
ANXNA1 Y21 EGFR binding, inward vesiculation (90, 91)
Cas1 (BCAR-1,Crk1) Y234, Y387, Y410 Migration, invasion, differentiation (65, 66)
CTNND1 (p120CAS) Y257, Y898 Uncharacterized (92, 93)
CDK1 T14/Y15 G1 arrest (94–98)
DYRK1B Y273 Catalytic domain autophosphorylation (99)
EphA2 Y575, Y772 Activation loop (100, 101)
Erbin (ErbB2IP) Y1104 Uncharacterized (102)
P38 T180/Y182 Kinase activation (59–61)
MPZL1 Y263 SHP2 docking (103)
PXN Y118 Cell polarization and motility (104, 105)
CD31 Y713 Src/SHP2 binding site (68–71)
SHP2 Y62 Uncharacterized (106, 107)
PTPR Y798 Grb2 docking (108, 109)
PTPR Y696 Uncharacterized
Fyn Y420 Activation (110)
FAK Y576 Activation (64, 111)
PRP4K Y849 Uncharacterized
SHC1 Y318 Ras activation, adaptor protein (112)
Lyn Y397, Y508 Enzymatic activation (Y397) and inhibition (Y508) (113)
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dynamics, correlation values obtained for the full data sets
were compared with a distribution of expected values gener-
ated from randomizing the original data set 100,000 times.
This approach provided an estimate of the statistical signifi-
cance of each correlation (p values), of which we considered
those that appeared with p  0.05 as significant. Although
there were relatively fewer overlaps of correlational changes,
the most interesting observation of the changes in correlation
coefficients were those following PF-4 treatment. Of the most
significant correlations (p  0.05) that we observed in our
system, there were only 65 correlations in the VEGF treatment
compared with 79 correlations that were significant following
co-treatment with PF-4 (Fig. 4). Of the total 144 unique cor-
relations between the two conditions, 18 are shared between
the two; 47 correlations are present only when VEGF is pres-
ent and disappear following PF-4 addition; 61 correlations are
present only when the two cytokines are simultaneously pres-
ent. Interestingly, these correlations with p  0.05 were all
strong, positive correlations; no negative correlations were
observed. An increase of signaling correlations following the
addition of PF-4 may be indicative of synergistic pathway
activations.
For a more intuitive understanding of the correlations with
p  0.05, signaling diagrams were plotted to assist in data
interpretation, where non-directional edges were representa-
tive of pairwise correlations (Fig. 5). The topologies of inter-
connected correlations are shown in the flow chart where red
edges indicate correlations present in VEGF, and green edges
indicate correlations present in VEGFPF-4. Roughly, the
topographical interpretation could be that the red edges are
lost or “inhibited,” whereas green edges are activated follow-
ing PF-4 treatment. From our correlation network analysis of
signaling topology changes, we observed that a significant
number of correlations appeared centering around EphA2
when PF-4 was present. It appeared that EphA2 phosphory-
lation was strongly correlated with Src family kinases, P38
MAPK, Shc1, DYRK1B, Catenin 1, and Annexin A1, a major-
ity of which have been previously associated with regulating
cell polarization and migration. On the other hand, many
correlations that were present in VEGF treatment involving
FAK disappeared following PF-4 addition. Likewise, loss of
correlations also occurred centering around CD31, including
correlations with EphA2, Shp2, receptor protein tyrosine
phosphatases.
With a focused subset of proteins such as ours, it is difficult
to generate a relevant model of pathways, but even a sparse
model characterizing relational associations can provide
some insights about how these proteins might influence ac-
tivities via pathway crosstalk. Our correlation network model
demonstrated CD31, P38, Fyn, and EphA2 to be central
nodes in both signaling environments to the changes in pro-
tein correlations following PF-4 treatment. Although PF-4 at-
tenuated many of the signals observed following VEGF treat-
ment, the signals that increased in correlation strength were
of particular interest. In fact, our significant correlations with
p  0.05 indicate positive correlations of multiple signaling
events; no negative correlations were found. Coupling the
presence of P38, Fyn, and EphA2 as central nodes with the
time course data collected (Fig. 2) suggests that VEGF with
FIG. 3. Heatmap of pairwise correlations in both VEGF with and without PF-4 treatments. Linear Pearson pairwise correlations for VEGF
with and without PF-4 were calculated for the phosphorylation fold changes measured for each time course. There are distinctive shifts in the
distribution of correlations between VEGF (A) and VEGFPF-4 (B) treatments, particularly with the higher number of negative correlations
present when PF-4 is absent. Phosphorylation changes were represented by the ratio of geometric means to a master control to reduce
potential effects of outliers in the population distribution.
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PF-4 tends to generally increase phosphorylation levels while
they decrease over time in VEGF only conditions.
Increased Phosphorylation and Total Protein Levels of
EphA2 are Indicated to Mediate PF-4 Signaling Effects—As a
follow-up of our analysis to validate the changes observed for
EphA2, Western blots on phosphorylated tyrosine 772 and
total EphA2 (Fig. 6) were performed. Seven replicates were
performed of the total and phospho-EphA2; a representative
Western shown in Fig. 6A. Both total and phosphorylated
EphA2 levels increased in HDMVECs that were treated with
PF-4 and VEGF as opposed to VEGF by itself. A semiquanti-
tative assessment of these concentrations was performed
using pixel intensity data of the Western blots. The mean
values and their standard errors were calculated from the
seven Westerns performed (Fig. 6B). There was an increase in
both phospho-Y772 and total EphA2 following the addition of
PF-4 at 30 min compared with VEGF by itself. Previous work
has found that binding of soluble ephA1 ligand to EphA2 can
initiate rapid activation and degradation of the total receptor
expression on cells, which PF-4 treatment may modulate
(48–50). Although no statistical significance was observed for
phospho-Y772 EphA2, statistical significance was found for
total EphA2 (p  0.05 by nonparametric statistical test Wilc-
oxon rank sum) between the two treatment conditions. Phos-
phorylation of tyrosine 594 and serine 897, sites known to be
responsible for kinase activity regulation of EphA2 following
Y772 phosphorylation, were difficult to observe in our system,
most likely because of rapid dephosphorylation by phospha-
tases and negative feedback loop interactions (51–53). These
phosphorylations were not detected in our MS or Western blot
samples (data not shown).
Attempts to finely tune total and phospho-EphA2 concen-
trations are difficult in primary HDMVECs, as phosphoinhibi-
tors, such as epigallicotechin gallate or lithocholic acid, were
difficult to use to inhibit EphA2 because of their nonspecific
effects on other multiple proteins (54, 55). Additionally, at-
tempts to reduce both phospho-EphA2 and total EphA2 con-
centrations using siRNA reduced cell retention because of the
requirement of EphA2 for cell-cell interaction and substrate
adhesion (Supplemental Data, Fig. S2).
DISCUSSION
With the advent of new systems-level phosphoproteomic
analysis methods, there is an increasing ability for large data
sets to be collected. In many cases, a more thorough survey
of the quantitative signaling in a system can be completed
(56). Unfortunately, the caveat to these large data sets are that
many of these phosphosites and protein targets are still not
completely characterized, leaving many of the possible roles
and functions as potential mysteries. Inflammation is a very
complex process convoluted by multiple factors and events.
In our system, we sought to use MS-based methods to shed
further light on how angiogenesis might occur in the inflam-
matory environment, when exposed to strong early positive
and negative regulating factors of angiogenesis.
Although there indeed were statistically significant differ-
ences at later time points (24–48 h) between VEGF with and
without PF-4 conditions, we observed the majority of these
differences to occur early in signaling, within the first 60 min of
treatment with the signaling factors. It appears that early
signaling mechanisms that are initiated by the two cytokines
influence the response behaviors observed long after. Past
FIG. 4. Heatmaps of significant pairwise correlations in VEGF and VEGF  PF-4 treatments. Following significance evaluation with
permutation tests, the majority of the pairwise correlations that remained are shown in the heatmaps above for VEGF (A) and VEGF  PF-4
(B), filtered for pairwise correlations that have p  0.05. Only positive correlations remain in either condition indicating that signaling in both
treatment conditions occurs cooperatively and not antagonistically with other proteins.
VEGF and PF-4 Cooperatively Modulate Migration Signaling Pathways
3712 Molecular & Cellular Proteomics 12.12
studies have found that early signaling pathway activation
informs cellular response long after the signaling pathway
actions have dissipated (57).
Similar to previous findings, we found that P38 MAPK
activity increased following PF-4 dosing (35). P38 MAPK
activity has been found to suppress endothelial cell migration
capacity and may have similar anti-migratory effects in our
system (58). This finding potentially agrees with previous data
on PF-4 signaling through P38 to exert its angiostatic activ-
ity, despite the considerable differences in experimental ap-
proaches (35). Although we used HDMVEC cultured on gels
(providing sprouting potential), the previous studies have fo-
cused primarily on cultured microvascular endothelial cells
directly on tissue culture plastic, thereby providing the possi-
bility that signaling dynamics may differ because of the envi-
ronments used. However, we did observe a decrease in T180
phosphorylation because of PF-4’s presence at 15 min, which
has been previously reported to be important in kinase acti-
vation. This decrease in threonine phosphorylation can affect
the overall efficacy of the kinase’s activity; as kinase activity is
strongly dependent on the presence of both phosphorylation
sites, particularly that of T180 (59–61).
We observed an initial decrease followed by an increase in
later times for FAK signaling when PF-4 was simultaneously
present with VEGF. Phosphorylation levels dipped below that
of VEGF at 60 min, before increasing at later time points to
levels higher than with VEGF alone. These phosphoprotein
level changes and protein interactions may reflect PF-4’s
regulatory influence on reducing endothelial migration, which
agree with previously found data (25, 30). The modulations in
Fyn and Lyn also lend credence to PF-4 influencing VEGF
mediated signaling. Although Fyn has been found to inhibit
cell migration following VEGF stimulation, Lyn promotes it as
a positive regulator (62). Both show increased signaling when
PF-4 is introduced, albeit Lyn has decreased signaling at 60
min, possibly contributing to PF-4’s ability to inhibit cell mi-
gration. FAK promotes angiogenesis and cell migration in a
Src-dependent manner in which PF-4 may interfere (63). The
notion that PF-4 is interfering with angiogenesis via Src family
kinases is also supported by the phosphorylation levels we
observe for Tyr576 on FAK, as it is a result of being in
proximity to Src family kinases, such as Fyn and Lyn (64).
Cas1 has been reported in previous literature to be important
in the regulation of cancer cells (65, 66), as well as dynamic
regulation of cytoskeletal components in conjunction with
FAK (67). The temporal observations and correlation topog-
raphy involved with PF-4 agree with previously reported find-
ings on PF-4 exerting its effects primarily by affecting cell
migration pathways.
In addition to the migratory pathways we observed being
modulated by PF-4, CD31 phosphorylation appeared to be
important in VEGF conditions, which disappeared when treat-
ment with PF-4 was applied. Phosphorylation of Y713 on
CD31 has been implicated to be a result of endothelial cell
FIG. 5. Correlative network connections between significant
phosphosites involved with the VEGF and PF-4 signaling. Signif-
icant pairwise correlations from above (p  0.05) were compared
between the two treatment conditions where HDMVECs were dosed
by VEGF alone or in conjunction with PF-4. To identify potential
dynamic changes in the topography of signaling, the presence or
absence of correlations between the two conditions were mapped
out. Black edges represent strong positive correlations present in
both the presence and absence of PF-4 co-treatments with VEGF.
Red edges indicate correlations present when endothelial cells were
dosed with VEGF only. Green edges indicate correlations that ap-
peared only when HDMVECs were simultaneously treated with PF-4
and VEGF and not with VEGF only. There were a larger number of
correlations that appeared only with VEGF treatment, such as those
centered around CD31 via shear stress response as well as migratory-
centric pathways involving FAK and Src Family Kinases. As ex-
pected by many of the reported angiostatic effects of PF-4, red edge
correlations (VEGF only) disappeared for FAK and other migratory
pathways. Interestingly, many new green edge correlations (VEGF 
PF-4) appeared around EphA2, contrary to its previously reported
roles in promoting angiogenesis.
VEGF and PF-4 Cooperatively Modulate Migration Signaling Pathways
Molecular & Cellular Proteomics 12.12 3713
response to shear flow, and is responsible for mediating T-cell
migration to inflamed environments (68–71). With the corre-
lation topography we observe, it appears that phospho-Y713
on CD31 may also be connected to the Src family kinases and
can influence cell migration pathways via this mechanism (72).
There is additional evidence of the possible influence of CD31
phosphorylation on migration behavior because of loss of
correlations with Cas1, SHC1, and Annexin A1.
In the context of angiogenesis, Annexin A1 has been re-
ported to have both angiogenic and anti-inflammatory effects
(73, 74). Furthermore, Annexin A1 has been positively linked
upstream to the ERK/MAPK pathway, with phosphorylation of
Annexin A1 associated with cell proliferation and survival (75).
Annexin I has also been found to be pro-angiogenic in its
ability to rescue angiogenic sprouts, although its definitive
role is still unclear (74). In our data, Annexin signaling is
attenuated and dampened with the introduction of PF-4.
Down-regulation of Annexin can potentially lead to down-
regulation of PLC group signaling and is recapitulated here in
our data as a result of stimulation with PF-4 (76).
It is difficult to assess the implications involved with all the
phosphosites identified in our system for proteins such as
SHC1, as its family of adaptor proteins is implicated in many
mechanisms including MAPK/ERK activation (77, 78). Like-
wise, assessment of Shp2 is difficult as characterization of
phospho-Y62 has yet to be reported in literature, although
Shp2 appears to play important roles in activating substrates
which are negatively regulated by phosphorylation (79). Al-
though the remaining proteins have generally been character-
ized for certain functions, their phosphorylation sites identified
in our data set are uncharacterized to date, making their
specific roles in the signaling network between VEGF and
PF-4 unknown. Furthermore, because of the complexity in-
herent in phosphoprotein signaling pathways, as well as the
large number of potential correlations observed for each of
the treatment conditions in this data set, it is difficult to glean
specific information about the behavior of every protein in
context of another.
Despite the difficulty in dealing with large complex net-
works, the flowchart assembled in Fig. 5 appears to generate
an interesting landscape centered on the Ephrin A2 receptor.
Although EphA2 has been reported to facilitate angiogenic
processes, in our system we found that EphA2 correlations
increased significantly when PF-4 was simultaneously present
with VEGF. In fact, many of the correlations did not appear
until after PF-4 was in the system. Ephrin and its class of RTK
receptors have been recognized as important regulators of
embryonic vascular development (class B) and vascular re-
modeling of mature tissues (class A) (80, 81). In mature adult
systems, EphA2 is associated with mediating vascular remod-
eling promoting cell migration and sprouting (82). EphA2 Y772
phosphorylation is implicated in mediating cell-cell interac-
tions, and from initial analysis of the time course data in the
context of previous studies, is required for progression of
angiogenesis (80, 83).
The addition of PF-4 delayed EphA2 phosphorylation dy-
namics relative to VEGF treatment alone. These changes in
signaling dynamics occur in tandem with FAK, Fyn, Lyn, and
P38. In fact, we also observed a number of positive corre-
lations of EphA2 with Src family kinases and P38, whose
phosphorylation have been reported to modulate cell migra-
tion (51, 84). As a result, we speculate that PF-4 stimulates
EphA2’s regulatory role on cell-cell interactions to reduce the
sprouting capacity of endothelial cells, or even implicate its
FIG. 6. Western blots of phosphorylated and total EphA2 indicate increases in both following co-treatment of HDMVECs with PF-4
at 30 min. Representative Westerns (A) are shown for both phospho- and total EphA2. Semiquantitative analysis of Western blots using pixel
intensity data (n  7) yielded increases in both total and phospho-EphA2 when PF-4 was added (B). The phospho-EphA2 increase agrees with
the signaling data obtained using mass spectrometry. These data indicate the potential role that EphA2 may play in mediating the signaling
crosstalk effects by EphA2. Although there was no statistical significance found in phosphorylation levels between VEGF and VEGF with PF-4
treatment, statistical significance was found for total EphA2 levels between the two treatment conditions (p  0.05, Wilcoxon rank sum test).
Error bars represent standard error.
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role in ensuring only the most robust sprouts form by prevent-
ing bulk cell invasion.
This “cohesive” behavior in which cells remain clustered
together has been speculated previously for initiation of tumor
metastasis and that EphA2 expression in tumor cells inhibits
their propensity to migrate (85). Tumor malignancy occurs
when these cells overcome this ephrin ligand inhibition,
through exploitation of vasculogenic mimicry. VE-cadherin
and EphA2 crosstalk has been found in melanoma vasculo-
genic mimicry where EphA2 colocalizes with VE-cadherin (86,
87). EphA2 has also been implicated in inhibiting integrin-
mediated adhesion, migration, and signaling, thereby contrib-
uting to a potential role in negative regulation following PF-4
treatment (88). This previous finding would also agree with
what we observe for signaling involved in migration; FAK
decreases over time in the presence of PF-4 and is negatively
regulated by EphA2. In addition, PF-4 treatments could also
potentially modulate EphA2 signaling dynamics by affecting
ephrinA1 presentation or expression, which can also induce
reverse signaling on neighboring cells to promote bulk home-
ostasis or single cell migration (48, 53). However, a caveat of
EphA2 signaling is that it has been implicated in many mo-
dalities of functions, often paradoxical for homeostatic sys-
tems compared with metastatic cancer models (51, 53, 82,
89). With the multiple functions that EphA2 can perform, it is
clear that regulation of EphA2 is crucial, and our data sug-
gests that its actions may be impinged or influenced by PF-4.
Despite our success with quantifying tyrosine phosphory-
lation signaling networks, we realize that a majority of signaling
data was lost because of the inherent difficulties working with
our system; a low signaling primary cell type in conjunction
with a highly concentrated matrix scaffold can drown out low
level signaling. This challenge was apparent in our original
captured list of phosphoproteomic data; we observed over
400 different phosphorylation sites across 350 unique pro-
teins that were significant hits. However, there was insufficient
quantitation in many of these measurements because of very
low level signaling. The presence of serum also introduces a
high proportion of background noise into our measurements
(as is observed in the error of some measurements shown in
Fig. 2). To recover some of the lost quantitation, we attempted
different data processing methods to increase our phospho-
protein coverage, including pooling time points into broader
categories. Although we slightly increased the number of
proteins that had statistical significance in temporal dynam-
ics, it was at the expense of correlative power in our topo-
graphical analysis (data not shown).
We have developed new processing methods to explore
pro- and anti-angiogenic signaling pathways in collagen gel
substrates. Relatively few studies have been performed in the
past on how PF-4 affects intracellular signaling in endothelial
cells. Our preliminary data indicate that PF-4 primarily induces
its angiostatic effects on microvascular endothelial cells via
pathways that control cell migration which precede sprouting
and invasion phenotype. From assessments of the time
course data and correlation network modeling, we have found
substantial implications of EphA2 signaling dynamics in neg-
atively regulating cell migration and angiogenesis following
stimulation, contrary to previous reports of its role in promot-
ing cell migration and sprouting. Our work indicates EphA2
signaling as an area of interest and future focus for under-
standing angiostatic mechanisms.
To our knowledge, this is the first large phosphoproteomic
signaling data set that has been collected from primary en-
dothelial cells cultured in a gel system. Although far from
being in vivo conditions, this culture system is more reflective
of physiological environments encountered as opposed to
standard two-dimensional cultures performed in the past. The
data gathered in this project not only provides new insight
about PF-4 and its interplay with VEGF on angiogenesis, but
can also be used to inform behavioral models of endothelial
cells (22), as well as follow-up analyses using targeted MS-
based approached, such as multiple reaction monitoring, to
gain increased coverage of the known and newly discovered
phosphosites reported here. These findings and their appli-
cations can build a foundation for future studies of molecular
interplay involved in inflammation and angiogenesis in phys-
iologically relevant models.
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